Search the Newsreel

Actuate Therapeutics (NASDAQ: ACTU) narrows loss but warns on cash runway

Actuate Therapeutics (ACTU) reported a narrowed net loss of $4.9 million for Q2 2026 and $10.5 million for the first half of 2026, driven by reduced R&D and G&A expenses. Despite this, the company faces significant going concern doubts as its $4.4 million in …

Definium Therapeutics (DFTX): Commodore Capital discloses 2.41M-share, 1.8% beneficial stake

Commodore Capital and related filers have disclosed a beneficial ownership of 2.41 million Common Shares, representing an 1.8% stake in Definium Therapeutics (DFTX) as of June 30, 2026. This position includes 2 million existing Common Shares and 410,000 shares acquirable through a pre-funded warrant. …

What Do Definium Therapeutics (DFTX) Phase 3 GAD Results Mean For DT120?

Definium Therapeutics (DFTX) reported positive Phase 3 results for DT120 ODT in generalized anxiety disorder (GAD), meeting primary and secondary efficacy endpoints. These results, which showed statistically significant and clinically meaningful benefits, are expected to support future regulatory filings for the drug. Investors are …

Biotechnology Value Fund group (TCRX) reports 9.99% TScan ownership with large warrants

The Biotechnology Value Fund (BVF) group and its affiliates have disclosed a 9.99% ownership stake in TScan Therapeutics (TCRX) as of June 30, 2026. This aggregate beneficial ownership includes 6,417,831 shares of Voting Common Stock, a significant portion of which are Pre-Funded Warrants exercisable …

Vistagen Therapeutics (VTGN) investor Chen Yu reports 6.7% warrant-based stake

Chen Yu, through TCG Crossover funds, has reported a 6.7% warrant-based stake in Vistagen Therapeutics (VTGN) via an amended Schedule 13G/A filing. TCG Crossover I holds 1.8% and TCG Crossover II holds 5.1%, with Chen Yu being the sole managing member of both general …

MMCAP and MM Asset Management (CRDL) reveal 21.3M-share Cardiol Therapeutics stake

MMCAP International Inc. SPC and MM Asset Management Inc. have reported a beneficial ownership of 21,310,099 Class A Common Shares in Cardiol Therapeutics Inc. (CRDL) as of June 30, 2026. This stake represents 17.6% of the company's Class A Common Shares, including both directly …

Vistagen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026

Sessa Capital discloses 8.8% Atrium Therapeutics (RNA) ownership through managed funds

Sessa Capital IM, L.P. and John Petry have reported a beneficial ownership of 1,500,000 shares of Atrium Therapeutics, Inc. common stock, which accounts for 8.8% of the outstanding shares. This disclosure was made via a SCHEDULE 13G SEC filing, indicating a passive investment. The …

CRISPR Therapeutics (CRSP): Orbis-led investors disclose 5.6% ownership stake

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have disclosed a combined beneficial ownership of 5,449,161 shares, or 5.6%, of CRISPR Therapeutics AG (CRSP) Common Stock as of June 30, 2026. Orbis holds the vast majority of these shares with sole voting …

Monte Rosa Therapeutics (GLUE) holders report sub‑5% stakes in amended 13G

Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an amended Schedule 13G for Monte Rosa Therapeutics (GLUE), indicating beneficial ownership below five percent of the outstanding common stock. Montanova Capital and Aaron Cowen each report a 4.2% stake, while Averill …

Monte Rosa Therapeutics (GLUE): Vestal Point discloses 4.6M-share, 5.4% ownership

Vestal Point Capital, LP and Ryan Wilder have disclosed a 5.4% beneficial ownership in Monte Rosa Therapeutics, Inc. (GLUE), totaling 4,600,000 shares of common stock. This passive investment is held through a fund and a managed account advised by Vestal Point Capital, with shared …

Clearwater Paper (CLW): Gate City Capital discloses 5.8% ownership stake in common stock

Gate City Capital Management, LLC and Michael Melby have disclosed a 5.8% passive ownership stake in Clearwater Paper Corp (CLW) common stock. This equates to 938,496 shares, over which they hold sole voting and dispositive power. The shares are managed through private investment funds …

Paradigm BioCapital reports 6.1% Viridian (VRDN) stake and 5.3% held by offshore fund

Paradigm BioCapital Advisors LP, its general partner, and Senai Asefaw M.D. have reported a beneficial ownership of 6,723,788 shares of Viridian Therapeutics (VRDN) common stock, representing 6.1% of the outstanding class as of June 30, 2026. Separately, Paradigm BioCapital International Fund Ltd. directly holds …

Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP announces a securities fraud class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR). Investors who purchased CAPR securities between December 17, 2025, and July 26, 2026, have until September 28, 2026, to seek lead plaintiff status. The lawsuit …

Edgewise Therapeutics (EWTX): Baker Bros. discloses 3.4% ownership in Schedule 13G/A

Trading Systems Reacting to (STOK) Volatility

The article analyzes Stoke Therapeutics Inc. (NASDAQ: STOK), noting a near-term neutral sentiment amidst mid and long-term strength, with an exceptional 61.2:1 risk-reward setup. It details three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for different risk profiles and provides multi-timeframe …

Canada Pension Plan (KLRA) discloses 5.6% Kailera Therapeutics ownership in 13G filing

The Canada Pension Plan Investment Board, through its subsidiary CPP Investment Board Private Holdings (4) Inc., has reported a beneficial ownership of 7,304,688 shares of Kailera Therapeutics, Inc. common stock. This accounts for 5.6% of the company's common stock, based on 129,565,608 shares outstanding …

Form 8K Autolus Therapeutics plc For: 11 August By Investing.com

This article from Investing.com reports on Autolus Therapeutics plc's Form 8K filing for August 11. It indicates that the company's stock, AUTL, is down 3.15%. The content primarily serves as a placeholder for the Form 8K information, alongside various market data and other unrelated …

Beam Therapeutics (BEAM): ARK Investment and Cathie Wood report 9.95% stake

ARK Investment Management LLC and Cathie Wood have reported a beneficial ownership of 9.95% in Beam Therapeutics Inc. (BEAM), totaling 10,234,862 shares. This disclosure, filed via a SCHEDULE 13G/A, indicates that ARK has significant voting and dispositive power over these shares. The filing also …

We're Keeping An Eye On Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate

This article examines Arcturus Therapeutics Holdings' cash burn rate and its implications for the company's future. It highlights the company's current cash reserves and how long they might last given its operating expenses. The analysis is crucial for investors to understand the company's financial …

Candel Therapeutics (NASDAQ:CADL) Stock Price Expected to Rise, Bank of America Analyst Says

Goldman Sachs Group (TNGX) discloses 6.0% beneficial stake in Tango Therapeutics

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have disclosed a 6.0% beneficial ownership stake in Tango Therapeutics, Inc. (TNGX) through a Schedule 13G filing. This holding amounts to 9,742,402.80 shares and signifies shared voting and dispositive power over …

Montanova Capital (ABEO) reports 0.9% beneficial stake in Abeona Therapeutics

Montanova Capital, LLC and Aaron Cowen have reported a beneficial ownership of 500,000 shares of Abeona Therapeutics Inc. common stock, which represents 0.9% of the outstanding class. This filing, an amended Schedule 13G, indicates that they now hold 5 percent or less of the …

Aligos Therapeutics Company Profile & Introduction

This document is intended to provide a company profile and introduction for Aligos Therapeutics. Further details about the company's operations, financial performance, and strategic direction would typically be included in a complete profile.

Akari Therapeutics targets mid-2027 phase 1 trial for AKTX-101

Akari Therapeutics reported its Q2 2026 financial results, including raising $8.6 million in gross proceeds. The company announced plans to initiate a Phase 1 clinical trial for its lead antibody drug conjugate candidate, AKTX-101, by mid-2027. AKTX-101 utilizes a proprietary PH1 payload targeting RNA …

AN2 Therapeutics (ANTX) director reports gift of 405,880 shares and 145,538 held

AN2 Therapeutics director Joseph S. Zakrzewski reported a bona fide gift of 405,880 shares of common stock, which were previously held indirectly through the Z3 Trust. He disavows beneficial ownership of these gifted shares. Following this transaction, Zakrzewski directly holds 145,538 shares of AN2 …

Kaplan Fox Investigates Fulcrum Therapeutics After 51% Stock Plunge Following Pociredir Program Halt

Kaplan Fox & Kilsheimer LLP has initiated an investigation into Fulcrum Therapeutics (NASDAQ: FULC) following a 51% stock drop. The plunge occurred after Fulcrum unexpectedly halted its pociredir program for sickle cell disease due to FDA concerns over its benefit-risk balance. The investigation will …

Neumora Therapeutics Releases Q2 2026 Financial Results

Neumora Therapeutics (NMRA) reported a diluted loss per share of $0.23 for Q2 2026, representing a net loss of $43.1 million. The clinical-stage biopharmaceutical company narrowed its per-share loss by 30.3% year-over-year compared to Q2 2025. This performance is typical for biopharma companies in …

Vistagen (VTGN) narrows quarterly loss, eyes FDA path after mixed fasedienol data

Vistagen (VTGN) reported a narrower net loss of $13.0 million for Q1 FY2027, an improvement from $15.1 million in the prior-year quarter, largely due to increased revenue and reduced R&D and G&A expenses. While its lead drug fasedienol missed its primary endpoint in the …

Cormorant Asset Management (MLTX) discloses 4.35% MoonLake Immunotherapeutics stake

Cormorant Asset Management, LP and Bihua Chen have disclosed a 4.35% beneficial ownership stake in MoonLake Immunotherapeutics (MLTX), totaling 3,205,433 Class A ordinary shares. This stake, reported via a SCHEDULE 13G/A filing, indicates shared voting and dispositive power over the shares and is based …

Vera Therapeutics Shares Up 9.7% as $425,000 Drug Launch Puts Focus on Cash Reserves

VistaGen Therapeutics earnings missed by $0.05, revenue topped estimates

Relmada Therapeutics (RLMD) gains 7.0% shareholder position from Squadron funds

Investment entities affiliated with Squadron Capital Management LLC have reported a beneficial ownership of 7.0% in Relmada Therapeutics, Inc. This stake, amounting to 7,350,000 shares, is held by Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank, based on shares …

Travere Therapeutics (TVTX) sees Armistice Capital report 1.67% ownership in 13G/A

Armistice Capital and Steven Boyd have filed an amended Schedule 13G disclosing a 1.67% beneficial ownership stake in Travere Therapeutics (TVTX). This ownership translates to 1,572,539 shares of common stock, with shared voting and dispositive power, falling below the 5% reporting threshold for a …

Travere Therapeutics (TVTX) Is Up 7.5% After Strong Q2 Revenue But Wider Net Loss - Has The Bull Case Changed?

Travere Therapeutics reported strong Q2 2026 revenue of US$169.58 million, a significant increase from the previous year, but also a wider net loss of US$34.8 million. The article discusses how this revenue growth, driven by its drug FILSPARI, reinforces the company's investment narrative focused …

Vistagen Therapeutics Releases Q1 2027 Financial Results

Vistagen Therapeutics reported a narrower loss for Q1 fiscal 2027, with a basic and diluted loss of $0.30 per share and a net loss of $13.0M. The company saw a significant revenue increase to $1.5M, up 504.9% year-over-year, as it continues to develop therapies …